Albers Jeffrey W.
SEC CIK 1638474 · EDGAR
BoughtSold
Most active insiders at SYRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir | — | $399.66M |
| 2 | Turtle Cameron | CEO, Dir | — | $9.99M |
| 3 | HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| 4 | Sloan Sheldon | Chief Medical Off | — | $7.35M |
| 5 | Burrows Scott L | CFO | — | $6.86M |
| 6 | King-Jones Heidy | See Remarks | — | $2.48M |
| 7 | Albers Jeffrey W. | Dir | — | $2.40M |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.39 | +5,000 | 5,000 | New | +$52.0K |
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $104.47 | -5,000 | 0 | -100% | -$522.4K |
| DMTI | 2026-08-10 21:31 | 2026-08-07 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $104.55 | -18.0K | 9,360 | -66% | -$1.88M |
| DMT | 2025-12-08 | 2025-12-08 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $89.76 | -5,000 | 2,252 | -69% | -$448.8K |
| DT | 2025-12-08 | 2025-12-08 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $14.18 | +5,000 | 5,000 | New | +$70.9K |
| DT | 2025-10-14 | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +5,000 | 5,000 | New | +$51.7K |
| DT | 2025-10-14 | 2025-10-13 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $59.19 | -5,000 | 0 | -100% | -$295.9K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $49.00 | -6,349 | 0 | -100% | -$311.1K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +6,349 | 6,349 | New | +$65.6K |
| I | 2024-11-08 | 2024-11-06 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale | $36.76 | -6,700 | 27.4K | -20% | -$246.3K |
| I | 2024-10-28 | 2024-10-25 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale | $36.43 | -300 | 34.1K | -0.9% | -$10.9K |
| DT | 2024-08-26 | 2024-08-26 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $49.10 | -5,000 | 0 | -100% | -$245.5K |
| DT | 2024-08-26 | 2024-08-26 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +5,000 | 5,000 | New | +$51.7K |
| DMT | 2024-02-21 | 2024-02-20+ | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +5,000 | 615 | New | +$51.7K |
| DMT | 2024-02-21 | 2024-02-20+ | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $39.05 | -5,000 | 0 | -100% | -$195.3K |
| DT | 2024-01-23 | 2024-01-23 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $30.05 | -10.0K | 0 | -100% | -$300.5K |
| DT | 2024-01-23 | 2024-01-23 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +10.0K | 10.0K | New | +$103.4K |
| DAI | 2023-12-08 | 2023-11-24 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | C - Cnv Deriv | $0.00 | +34.4K | 34.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations